Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of repeated high-dose medroxyprogesterone acetate for recurrent early endometrial lesions
jRCTs031200256Phase 2Active, not recruiting
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of medroxyprogesterone acetate in endometrial cancer (EC) and Endometrial intraepithelial neoplasia (EIN). Primary endpoint: 2-year recurrence-free survival rate. Started Jan 2021; status: active, not recruiting.
02
Drugs
medroxyprogesterone acetate
03
Conditions
endometrial cancer (EC)Endometrial intraepithelial neoplasia (EIN)
Beyond the preview
Go deeper on jRCTs031200256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200256.